Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard Parnes

Date Posted: 

Monday, May 13, 2019

In 2003, results from the Prostate Cancer Prevention Trial (PCPT)—an NCI-funded randomized clinical trial with nearly 19,000 participants—showed that men aged 55 and older who used the drug finasteride daily for 7 years had a substantially reduced risk of developing prostate cancer.

In this interview, Howard Parnes, MD, of NCI’s Division of Cancer Prevention and a PCPT investigator, talks about the findings from these subsequent studies and what they mean for the use of finasteride today.

Read the NCI Cancer Currents Blog post

For more information view the full article at: 

NCI Cancer Currents Blog